Zenlabs Ethica Ltd
₹ 19.5
-0.41%
17 Mar
- close price
About
Incorporated in 1993, Zenlabs Ethica Ltd deals in marketing and distribution of pharmaceutical products.[1]
Key Points
- Market Cap ₹ 12.7 Cr.
- Current Price ₹ 19.5
- High / Low ₹ 39.2 / 18.0
- Stock P/E 55.1
- Book Value ₹ 16.2
- Dividend Yield 0.00 %
- ROCE 5.69 %
- ROE 2.63 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -2.55% over past five years.
- Company has a low return on equity of 5.35% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.16%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00 | -0.00 | 15.09 | 78.73 | 69.85 | 65.37 | 58.50 | 56.64 | 69.09 | 66.89 | 58.56 | 51.42 | 49.33 | |
| 0.04 | 0.05 | 14.89 | 77.28 | 68.00 | 63.28 | 59.20 | 54.89 | 66.70 | 63.98 | 56.15 | 48.84 | 47.15 | |
| Operating Profit | -0.04 | -0.05 | 0.20 | 1.45 | 1.85 | 2.09 | -0.70 | 1.75 | 2.39 | 2.91 | 2.41 | 2.58 | 2.18 |
| OPM % | 1.33% | 1.84% | 2.65% | 3.20% | -1.20% | 3.09% | 3.46% | 4.35% | 4.12% | 5.02% | 4.42% | ||
| -0.00 | -0.00 | -0.03 | 0.08 | 0.10 | 0.10 | 0.05 | 0.11 | 0.09 | -0.45 | 0.30 | 0.04 | -1.98 | |
| Interest | -0.00 | -0.00 | 0.02 | 0.10 | 0.09 | 0.07 | 0.23 | 0.29 | 0.37 | 0.53 | 0.83 | 0.93 | 0.86 |
| Depreciation | 0.01 | 0.01 | 0.06 | 0.20 | 0.20 | 0.23 | 0.29 | 0.71 | 0.89 | 1.25 | 1.29 | 1.26 | 1.07 |
| Profit before tax | -0.05 | -0.06 | 0.09 | 1.23 | 1.66 | 1.89 | -1.17 | 0.86 | 1.22 | 0.68 | 0.59 | 0.43 | -1.73 |
| Tax % | -0.00% | 16.67% | -88.89% | 21.95% | 29.52% | 32.80% | -36.75% | 10.47% | 36.07% | 26.47% | 27.12% | 37.21% | |
| -0.06 | -0.07 | 0.17 | 0.95 | 1.16 | 1.26 | -0.73 | 0.77 | 0.78 | 0.49 | 0.42 | 0.27 | -1.85 | |
| EPS in Rs | -0.16 | -0.18 | 0.26 | 1.46 | 1.78 | 1.94 | -1.12 | 1.18 | 1.20 | 0.75 | 0.65 | 0.41 | -2.84 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | 16.32% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | 33.21% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -3% |
| 3 Years: | -9% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 19% |
| 3 Years: | -30% |
| TTM: | -30% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -4% |
| 3 Years: | -35% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 7% |
| 3 Years: | 5% |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.62 | 3.62 | 6.20 | 6.20 | 6.20 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 |
| Reserves | -1.57 | -1.65 | -1.41 | -0.41 | 0.81 | 1.77 | 0.90 | 2.05 | 2.82 | 3.19 | 3.61 | 3.92 | 4.04 |
| -0.00 | -0.00 | 1.09 | 0.96 | 0.85 | 0.60 | 0.73 | 2.60 | 3.90 | 5.85 | 14.86 | 12.71 | 9.77 | |
| 1.75 | 1.77 | 24.49 | 26.62 | 21.96 | 26.01 | 25.85 | 21.04 | 24.66 | 27.95 | 15.28 | 17.48 | 19.51 | |
| Total Liabilities | 3.80 | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 40.26 | 40.62 | 39.83 |
| 0.09 | 0.06 | 1.68 | 1.50 | 1.33 | 1.36 | 1.12 | 3.51 | 3.53 | 5.03 | 3.70 | 2.29 | 1.53 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | 1.25 | 0.95 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
| 3.71 | 3.68 | 27.44 | 30.92 | 27.79 | 32.83 | 32.17 | 27.99 | 33.66 | 37.77 | 35.86 | 37.63 | 37.60 | |
| Total Assets | 3.80 | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 40.26 | 40.62 | 39.83 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | 0.02 | 0.92 | -1.06 | 0.36 | 0.80 | 0.45 | -8.41 | -0.38 | 1.52 | -9.06 | 3.83 | |
| -0.00 | -0.00 | -1.69 | -0.02 | -0.03 | -0.22 | 0.01 | 0.15 | -0.00 | -1.47 | 0.11 | 0.14 | |
| -0.00 | -0.00 | 3.23 | -0.27 | -0.23 | -0.14 | -0.03 | -0.52 | 0.31 | 0.06 | 8.24 | -3.08 | |
| Net Cash Flow | -0.01 | 0.02 | 2.47 | -1.35 | 0.09 | 0.44 | 0.43 | -8.78 | -0.07 | 0.11 | -0.71 | 0.88 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 398.14 | 107.65 | 126.40 | 139.37 | 138.76 | 121.67 | 109.57 | 118.41 | 129.21 | 138.70 | ||
| Inventory Days | 249.62 | 34.42 | 11.12 | 31.23 | 33.95 | 40.46 | 56.05 | 77.85 | 100.05 | 128.43 | ||
| Days Payable | 665.46 | 136.41 | 125.88 | 161.27 | 165.31 | 150.28 | 141.30 | 174.04 | 101.21 | 140.00 | ||
| Cash Conversion Cycle | -17.70 | 5.66 | 11.64 | 9.33 | 7.40 | 11.85 | 24.32 | 22.21 | 128.04 | 127.13 | ||
| Working Capital Days | 4.84 | 13.40 | 21.95 | 28.42 | 24.02 | 27.97 | 35.34 | 34.98 | 47.31 | 52.74 | ||
| ROCE % | -2.40% | -2.99% | 9.94% | 21.06% | 23.96% | 24.13% | -11.05% | 12.02% | 13.04% | 12.44% | 7.01% | 5.69% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Capital Turnover Ratio times |
|
||||||||||
| Number of Permanent Employees number |
|||||||||||
| Trade Receivables Turnover Ratio times |
|||||||||||
Requires Premium
Requires Premium
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
2 Mar - Amit Kumar resigned as Company Secretary & Compliance Officer effective 02 March 2026 (resignation dated 23 Feb 2026).
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
2 Mar - Amit Kumar resigned as Company Secretary & Compliance Officer effective March 2, 2026 (personal reasons).
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015
23 Feb - Zenlabs Ethica received Feb 23, 2026 GST demand totalling Rs.1,170,977 (tax, credit, interest, penalty).
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Feb - Submission of Newspaper advertisement for the publication of extract of Un-audited financial results for the quarter and nine months ended on 31st December 2025
-
Announcement under Regulation 30 (LODR)-Change in Management
7 Feb - Amit Kumar appointed Company Secretary & Compliance Officer effective 07.02.2026 (ACS 78790).
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
a) ZEL is a part of the Preet Remedies Group. It is a WHO–GMP certified contract manufacturing pharmaceutical firm which operates across manufacturing and distributing diversified pharmaceutical formulations under multiple divisions (Zenlabs, Coles Pharma, Mega Star), servicing both domestic and international markets including Southeast Asia.
b) The company does third party manufacturing for Preet Remedies Group which has 5 production units namely Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Unit I & II, and Alpha Products. At any of these facilities, the minimum
order quantity offered is 2000 boxes
of drugs.
c) The company is also into private label manufacturing of different pharmaceutical products.